Document:

EX-10.32

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with the
Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 Exhibit 10.32 

 

			
	 UNIVERSITY OF CALIFORNIA, BERKELEY
  

OFFICE OF TECHNOLOGY LICENSING
		

            

  
  

 
 AMENDMENT # 1 

TO: 
 THE EXCLUSIVE
LICENSE AGREEMENT BETWEEN ADURO BIOTECH INC. AND 
 THE REGENTS 

FOR 

CYCLIC-DI-NUCLEOTIDES THAT STIMULATE HUMAN STING VARIANTS 

ANDSTIMULATOR OF INTERFERON GENE 

UC Case No.: [*] 
 Agreement
Control No. 2015-04-0045 
  
  

 
 This first amendment (“AMENDMENT # 1”) to
the exclusive license agreement (the “AGREEMENT”) between the REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation, whose legal address is 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, acting through
its Office of Technology Licensing, at the University of California, Berkeley, 2150 Shattuck Avenue, Suite 510, Berkeley, CA 94704-1347 (“REGENTS”) and ADURO BIOTECH, INC, a Delaware corporation having a principal place of business
at 626 Bancroft Way, 3C, Berkeley, CA 94710 (“LICENSEE”) is effective as of March 4, 2015. 
 The parties agree to amend the referenced license
agreement as follows: 
 Article 2 (DEFINITIONS), substitute paragraph 2.5 in its entirety with the following: 

 

	 	2.5	 “Joint PATENT RIGHTS” means (i) U.S. Patent Application Serial Number [*] and assigned to REGENTS and LICENSEE; (ii) U.S. Patent Application
Serial Number [*] and assigned to REGENTS and LICENSEE; (iii) U.S. Patent Application Serial Number [*] and assigned to REGENTS and LICENSEE; (iv) PCT Application Serial Number [*] and assigned to REGENTS and LICENSEE; (v) any patent applications,
utility models, inventors certificates, invention registrations, continuing applications, divisional applications, substitutions, continuation-in-

  

					
	 Aduro Biotech Inc.
 CONFIDENTIAL
		Page 1 of 2		
Amend. # 1 (REVC) to EXCL 
2015-04-0045
 UC Case No.: B13-136 & B14-143

	 	
part applications, and equivalents thereof in any jurisdiction anywhere in the world, in each case to the extent that claims in such filings are entitled to the filing date of the patent
applications in (i)-(iv); and (vi) any granted patents issuing on (i)-(v) including any reissues, re-examinations, or extensions thereof. 

All remaining terms and conditions of the AGREEMENT between Licensee and Regents, which bears an effective date of September 25, 2014, remain in full force
and effect. 
 IN WITNESS WHEREOF, the parties hereto have executed this Amendment # 1 in duplicate originals by their duly authorized officers and
representatives. The parties to this document agree that a copy of the original signature to this Agreement (including an electronic copy) may be used for any and all purposes for which the original signature may have been used. The parties further
waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original signature. 
  

									
	THE REGENTS OF THE				ADURO BIOTECH, INC.
	UNIVERSITY OF CALIFORNIA						
					
	By		         /s/ Irvin J. Mettler
				By		         /s/ Thomas Dubensky

					
			         Irvin J. Mettler, Ph.D.

        Associate Director

        Office of Technology Licensing
				Name		              Thomas
Dubensky

					  
 Title
		              Chief Scientific
Officer

					
	Date		   March 6, 2015
				Date		   03.05.2015

  

					
	 Aduro Biotech Inc.
 CONFIDENTIAL
		Page 2 of 2		
Amend. # 1 (REVC) to EXCL 
2015-04-0045
 UC Case No.: B13-136 & B14-143

[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to
Rule 406 of the Securities Act of 1933, as amended.EX-10.33

 Exhibit 10.33 
  

ADURO BIOTECH, INC. 

SEVERANCE PLAN 
 AND

 SUMMARY PLAN DESCRIPTION 
  

Plan Effective Date: March 4, 2015 
  

 

  
 -1- 

 ADURO BIOTECH, INC. 

SEVERANCE PLAN 
 AND

 SUMMARY PLAN DESCRIPTION 

The Aduro Biotech, Inc. Severance Plan (the “Plan”) provides severance benefits to a select group of management or highly
compensated employees of Aduro Biotech, Inc., a Delaware corporation (the “Company”). The Plan is effective for eligible employees who receive and execute a Severance Agreement (an “Agreement”) and who otherwise
satisfy the conditions set forth in such Agreement and the provisions of this Plan (“Covered Employees”). 
 This Plan is
designed to be an “employee welfare benefit plan,” as defined in Section 3(1) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”). This Plan is governed by ERISA and, to the extent applicable, the
laws of the State of Delaware, without reference to the conflict of law provisions thereof. 
 This document and your Agreement constitute
both the official plan document and the required summary plan description under ERISA. 
  

	I.	ELIGIBILITY 

 You will become a Covered Employee participant in the Plan only if you: (i)
are selected by the Company to be eligible to participate in this Plan, (ii) receive and sign the Agreement (attached hereto as Exhibit A) indicating your agreement to be bound by the terms of this Plan and the Agreement and (iii) timely return such
signed Agreement to the Company. 
  

	II.	BENEFITS 

 If you are a Covered Employee, you shall be eligible for severance benefits at
such times and in such amounts as may be specified in your Agreement. 
  

	III.	OTHER IMPORTANT INFORMATION 

 A. Plan Administration. As the Plan Administrator,
the Company has the full and sole discretionary authority to administer and interpret the Plan, including discretionary authority to determine eligibility for participation in and for benefits under the Plan, to determine the amount of benefits (if
any) payable per participant, and to interpret any terms of this document. All determinations by the Plan Administrator will be final and conclusive upon all persons and be given the maximum possible deference allowed by law. The Plan Administrator
is the “named fiduciary” of the Plan for purposes of ERISA and will be subject to the applicable fiduciary standards of ERISA when acting in such capacity. The Company may delegate in writing to any other person all or a portion of its
authority or responsibility with respect to the Plan. 
 B. Source of Benefits. The Plan is unfunded, and all severance benefits will
be paid from the general assets of the Company or its successor. No contributions are required under the Plan. 

  
 -2- 

 C. Claims Procedure. If you are a Covered Employee and believe you have been incorrectly
denied a benefit or are entitled to a greater benefit than the benefit you received under the Plan, you may submit a signed, written application to the Company’s Chief Executive Officer (“Claims Administrator”). You will be
notified in writing of the approval or denial of this claim within ninety (90) days of the date that the Claims Administrator receives the claim, unless special circumstances require an extension of time for processing the claim. In the event an
extension is necessary, you will be provided written notice prior to the end of the initial ninety (90) day period indicating the special circumstances requiring the extension and the date by which the Claims Administrator expects to notify you of
approval or denial of the claim. In no event will an extension extend beyond ninety (90) days after the end of the initial ninety (90) day period. If your claim is denied, the written notification will state specific reasons for the denial, make
specific reference to the Plan provision(s) on which the denial is based, and provide a description of any material or information necessary for you to perfect the claim and why such material or information is necessary. The written notification
will also provide a description of the Plan’s review procedures and the applicable time limits, including a statement of your right to bring a civil suit under section 502(a) of ERISA following denial of your claim on review. 

You will have sixty (60) days from receipt of the written notification of the denial of your claim to file a signed, written request for a
full and fair review of the denial by a review panel which will be a named fiduciary of the Plan for purposes of such review. This request should include the reasons you are requesting a review and may include facts supporting your request and any
other relevant comments, documents, records and other information relating to your claim. Upon request and free of charge, you will be provided with reasonable access to, and copies of, all documents, records and other information relevant to your
claim, including any document, record or other information that was relied upon in, or submitted, considered or generated in the course of, denying your claim. A final, written determination of your eligibility for benefits shall be made within
sixty (60) days of receipt of your request for review, unless special circumstances require an extension of time for processing the claim, in which case you will be provided written notice of the reasons for the delay within the initial sixty (60)
day period and the date by which you should expect notification of approval or denial of your claim. This review will take into account all comments, documents, records and other information submitted by you relating to your claim, whether or not
submitted or considered in the initial review of your claim. In no event will an extension extend beyond sixty (60) days after the end of the initial sixty (60) day period. If an extension is required because you fail to submit information that is
necessary to decide your claim, the period for making the benefit determination on review will be tolled from the date the notice of extension is sent to you until the date on which you respond to the request for additional information. If your
claim is denied on review, the written notification will state specific reasons for the denial, make specific reference to the Plan provision(s) on which the denial is based and state that you are entitled to receive upon request, and free of
charge, reasonable access to, and copies of, all documents, records and other information relevant to your claim, including any document, record or other information that was relied upon in, or submitted, considered or generated in the course of,
denying your claim. The written notification will also include a statement of your right to bring an action under section 502(a) of ERISA. 

If your claim is initially denied or is denied upon review, you are entitled to receive upon request, and free of charge, reasonable access
to, and copies of, any document, record or other information that demonstrates that (1) your claim was denied in accordance with the terms of the 

  
 -3- 

 
Plan, and (2) the provisions of the Plan have been consistently applied to similarly situated Plan participants, if any. In pursuing any of your rights set forth in this section, your authorized
representative may act on your behalf. 
 If you do not receive notice within the time periods described above, whether on initial
determination or review, you may initiate a lawsuit under Section 502(a) of ERISA. 
 D. Prior Plans Superseded. The Plan supersedes
any and all prior separation, change in control, severance and salary continuation arrangements, programs and/or similar plans that may previously have been offered or provided by the Company (and its predecessors-in-interest) to Covered Employees
provided, however, that an Agreement may provide for the survival of some or all of the provisions in such prior arrangements. 
 E. Plan
Amendment or Termination. The Company reserves the right to amend or terminate the Plan at any time, in whole or in part, and in any manner, and for any reason. Notwithstanding the foregoing, unless a Covered Employee provides written consent to
the contrary, any termination or amendment of the Plan will be effective only after two (2) years advance written notice to a Covered Employee if such amendment or termination would result in a reduction of benefits that the Covered Employee would
have otherwise been able to receive under the pre-amended or terminated Plan. 
 F. At-Will Employment. No provision of the Plan is
intended to provide you with any right to continue as an employee with the Company or in any other capacity, for any specific period of time, or otherwise affect the right of the Company to terminate the employment or service of any individual at
any time for any reason or no reason, with or without cause. 
 G. Section 409A of the Internal Revenue Code. This Plan is intended
to provide severance benefits pursuant to an employee welfare benefit plan subject to ERISA. The Plan is not intended to constitute a “nonqualified deferred compensation plan” within the meaning of Section 409A of the Internal Revenue Code
(“Code”). Notwithstanding the foregoing, in the event this Plan or any benefit paid under this Plan to a Covered Employee is deemed to be subject to Code Section 409A, such Covered Employee consents to the Company’s adoption of
such conforming amendments as the Company deems advisable or necessary, in its sole discretion, to comply with Code Section 409A and avoid the imposition of taxes under Code Section 409A. Each payment made pursuant to any provision of this Plan
shall be considered a separate payment and not one of a series of payments for purposes of Code Section 409A. While it is intended that all payments and benefits provided under this Plan to Covered Employees will be exempt from or comply with Code
Section 409A, the Company makes no representation or covenant to ensure that the payments under this Plan are exempt from or compliant with Code Section 409A. The Company will have no liability to Covered Employees or any other party if a payment or
benefit under this Plan is challenged by any taxing authority or is ultimately determined not to be exempt or compliant. The Covered Employees further understand and agree that the Covered Employees will be entirely responsible for any and all taxes
on any benefits payable to the Covered Employees as a result of this Plan. In addition, if upon a Covered Employee’s “separation from service” within the meaning of Code Section 409A, he or she is then a “specified employee”
(as defined in Code Section 409A), then solely to the extent necessary to comply with Code Section 409A and avoid the imposition of taxes under Code Section 409A, the Company shall defer payment of “nonqualified deferred compensation”
subject to Code Section 409A payable as a result of and within six (6) months following such 

  
 -4- 

 
“separation from service” under this Plan until the earlier of (i) the first business day of the seventh month following the Covered Employee’s “separation from service,”
or (ii) ten (10) days after the Company receives written confirmation of the Covered Employee’s death. Any such delayed payments shall be made without interest. 

H. Indemnification. The Company agrees to indemnify its officers and employees and the members of the Board of Directors of the Company
from all liabilities from their acts or omissions in connection with the administration, amendment or termination of the Plan, to the maximum extent permitted by applicable law. 

I. Severability. If any provision of the Plan is held invalid or unenforceable, its invalidity or unenforceability will not affect any
other provision of the Plan, and the Plan will be construed and enforced as if such provision had not been included. 
 J. Headings.
Headings in this Plan document are for purposes of reference only and will not limit or otherwise affect the meaning hereof. 
  

	IV.	STATEMENT OF ERISA RIGHTS 

 As a participant in the Plan you are entitled to certain
rights and protections under ERISA. ERISA provides that all Plan participants shall be entitled to: 
 A. Receive Information About Your
Plan and Benefits 
 Examine, without charge, at the Plan Administrator’s office and at other specified locations, such as work
sites, all documents governing the Plan. 
 Obtain, upon written request to the Plan Administrator, copies of documents governing the
operation of the Plan. The Plan Administrator may impose a reasonable charge for the copies. 
 B. Prudent Actions by Plan Fiduciaries

 In addition to creating rights for Plan participants, ERISA imposes duties upon the people who are responsible for the operation of
the employee benefit plan. The people who operate your Plan, called “fiduciaries” of the Plan, have a duty to do so prudently and in the interest of you and other Plan participants and beneficiaries. No one, including your employer or any
other person, may fire you or otherwise discriminate against you in any way to prevent you from obtaining a welfare benefit or exercising your rights under ERISA. 

C. Enforce Your Rights 

If your claim for a welfare benefit is denied or ignored, in whole or in part, you have a right to know why this was done, to obtain copies of
documents relating to the decision without charge, and to appeal any denial, all within certain time schedules. 
 Under ERISA, there are
steps you can take to enforce the above rights. For instance, if you request a copy of Plan documents and do not receive it within 30 days, you may file suit in a federal court. In such a case, the court may require the Plan Administrator to provide
the materials and pay you up to $110.00 per day until you receive the materials, unless the materials 

  
 -5- 

 
were not sent because of reasons beyond the control of the Plan Administrator. If you have a claim for benefits which is denied or ignored, in whole or in part, you may file suit in a state or
federal court after you have completed the Plan’s administrative appeals process. If you are discriminated against for asserting your rights, you may seek assistance from the U.S. Department of Labor, or you may file suit in a federal court.
The court will decide who should pay court costs and legal fees. If you are successful, the court may order the person you have sued to pay these costs and fees. If you lose, the court may order you to pay these costs and fees, for example, if it
finds your claim is frivolous. 
 D. Assistance With Your Questions 

If you have any questions about the Plan, you should contact the Plan Administrator. If you have any questions about this statement or about
your rights under ERISA, or if you need assistance in obtaining documents from the Plan Administrator, you should contact the nearest office of the Employee Benefits Security Administration, U.S. Department of Labor, listed in your telephone
directory, or the Division of Technical Assistance and Inquiries, Employee Benefits Security Administration, U.S. Department of Labor, 200 Constitution Avenue N.W., Washington, D.C. 20210. You may also obtain certain publications about your
rights and responsibilities under ERISA by calling the publications hotline of the Employee Benefits Security Administration. 

ADDITIONAL PLAN INFORMATION 
  

			
	 Name of Plan:
		Aduro Biotech, Inc. Severance Plan
		
	 Employer Sponsoring Plan:
		 Aduro Biotech, Inc.
 626 Bancroft Way 3C,
Berkeley, CA 94710

		
	 Employer Identification Number:
		94-3348934
		
	 Plan Number:
		555
		
	 Plan Year:
		Calendar Year
		
	 Plan Administrator:
		 Aduro Biotech, Inc.
 c/o Chief Executive
Officer
 626 Bancroft Way 3C, Berkeley, CA 94710

Telephone No. (510) 848-4400

		
	 Agent for Service of Legal Process:
		Plan Administrator, at the above address
		
	 Type of Plan:
		Employee Welfare Benefit Plan providing for severance benefits
		
	 Plan Costs:
		The cost of the Plan is paid by Aduro Biotech, Inc.
		
	 Type of Administration:
		Self-administered by the Plan Administrator

  
 -6- 

 IN WITNESS WHEREOF, the Company has caused this Plan to be duly executed as of March 4,
2015. 
  

	
	ADURO BIOTECH, INC.
	
	      /s/ Stephen T. Isaacs

	 By:    Stephen T. Isaacs

	 Title:  Chief Executive Officer

  
 -7-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}]]